文献速递内脏/肾动脉与血管畸形

覆膜支架与裸金属支架治疗慢性肠系膜缺血的系统评价与Meta分析

Covered Versus Bare-Metal Stents in Chronic Mesenteric Ischemia Treatment: A Systematic Review and Meta-Analysis.
PubMed 文献 · Ann Vasc Surg · 2025-01-24

该系统评价与Meta分析纳入1项随机临床试验和5项观察性研究,比较覆膜支架与裸金属支架治疗慢性肠系膜缺血的效果。汇总分析显示,覆膜支架组的一期通畅率(HR 0.40,95%CI 0.23-0.68,P<0.01)和无再干预率(HR 0.30,95%CI 0.13-0.71,P<0.01)均优于裸金属支架组。作者认为覆膜支架可能作为首选支架选择,但需谨慎解读,因研究数量有限、偏倚风险中至严重且存在显著异质性。

要点

  • 覆膜支架组一期通畅率优于裸金属支架组(HR 0.40,95%CI 0.23-0.68,P<0.01)。
  • 覆膜支架组无再干预率优于裸金属支架组(HR 0.30,95%CI 0.13-0.71,P<0.01)。
  • 作者认为覆膜支架可能作为慢性肠系膜缺血患者的首选支架选择。

核心结论

  • 在腹腔干和肠系膜上动脉行腔内血管成形术并置入支架的患者中,使用覆膜支架的一期通畅率和无再干预率均优于裸金属支架。
  • 这些发现提示覆膜支架结局更优,可能建议将其作为慢性肠系膜缺血患者的首选支架选择。
  • 由于研究数量有限、纳入数据存在中至严重偏倚风险以及观察到显著异质性,这些发现应谨慎解读。
  • 需要进一步的高质量临床试验来验证这些结果并加强临床实践的循证基础。

研究设计与样本

  • 系统检索Pubmed、Embase和Cochrane Central Register of Controlled Trials数据库,纳入慢性肠系膜缺血患者接受裸金属支架或覆膜支架置入的研究。
  • 共纳入1项随机临床试验和5项观察性研究。
  • 主要结局为一期通畅率和无再干预率,统计分析使用R版本3.6。

主要发现

  • 汇总分析中,覆膜支架组的一期通畅率高于裸金属支架组(HR 0.40,95%CI 0.23-0.68,P<0.01)。
  • 覆膜支架组的无再干预率显著优于裸金属支架组(HR 0.30,95%CI 0.13-0.71,P<0.01)。

临床怎么用

  • 作者认为,对于慢性肠系膜缺血患者,覆膜支架可能作为首选支架选择。
  • 作者指出,这些发现应谨慎解读,并需要进一步的高质量临床试验来验证。

局限性

  • 研究数量有限。
  • 纳入数据存在中至严重偏倚风险。
  • 观察到显著异质性。
  • 需要进一步的高质量临床试验来验证这些结果并加强临床实践的循证基础。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The main treatment for chronic mesenteric ischemia (CMI) is revascularization, typically achieved through stent angioplasty of the superior mesenteric artery, and in certain cases, the celiac trunk. However, long-term outcomes using bare-metal stents (BMSs) have been less than satisfactory. Therefore, we aimed to compare the performance of covered stents (CSs) versus BMSs in patients treated for CMI. METHODS: Pubmed, Embase, and Cochrane Central Register of Controlled Trials databases were systematically searched for studies of patients with CMI who underwent stenting procedures using BMS or CS. The main outcomes were primary patency and freedom from reintervention. Statistical analysis was performed using R version 3.6. RESULTS: One randomized clinical trial and 5 observational studies were included. In the pooled analysis, patients undergoing the covered stenting approach had a higher primary patency (hazard ratio 0.40; 95% confidence interval 0.23-0.68; P < 0.01). Additionally, CS also demonstrated significantly superior freedom from reintervention when compared to BMS patients (hazard ratio 0.30; 95% confidence interval 0.13-0.71; P < 0.01). CONCLUSION: In patients undergoing transluminal angioplasty with stent placement both in the celiac trunk and superior mesenteric artery, the use of CS indicated superior primary patency and a higher rate of freedom from reintervention than BMS. These findings indicate superior outcomes with CS and may suggest their use as the preferred stent option in patients with CMI. However, these findings should be interpreted cautiously due to the limited number of studies, the moderate to serious risk of bias in the included data, and the significant heterogeneity observed. Further high-quality clinical trials are necessary to validate these results and strengthen the evidence base for clinical practice.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Dias Miranda NC, Marimpietri FS, Marcolin Miranda L, et al. Covered Versus Bare-Metal Stents in Chronic Mesenteric Ischemia Treatment: A Systematic Review and Meta-Analysis. Ann Vasc Surg. 2025. PMID: 39864517. doi:10.1016/j.avsg.2024.12.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。